In 2013, the contract development and manufacturing organisations AAIPharma Services and Cambridge Major Laboratories merged and told this publication there would be future investment in capital expansion of new capabilities to further support the growing demand from its joint customer base.
And last week, the entity announced it was investing $10.7m (€9.7m) to build a new facility at its Cortex Innovation Center in St Louis, Missouri, to rehouse its current analytical testing services currently located nearby.
The CDMO said the new site was a response to increased customer demand and the growing trend of analytical testing outsourcing from pharma and biopharma clients. CEO Stephan Kutzer added the relocation comes at a critical time for his company's growth:
“Analytical testing is an instrumental pillar of our company and we are excited to provide our customers and the market with innovative testing solutions as part of our overall service offering including our other pillars in API, Drug Product and Development Services.”
Construction is set to be completed by the end of this year, with the first quarter 2017 seeing a transition period from the existing facility, with AAI/CML pledging there will be no disruption to any client projects.
It will provide new testing capabilities, such as glass and plastic containers testing for pharmaceutical use, elemental impurities, disinfectant qualification and efficacy studies, complementing analytical current services being offered by the firm.